Strategic Partnerships There is active expansion through regional and international partnerships, including agreements with Palex Medical (Spain/Portugal), The Scientific Group (SSA), Hyupjin (Korea), and the IRB Barcelona ecosystem. Use these relationships to identify co-marketing, distribution, and clinical adoption opportunities in new geographies and hospital networks.

Clinical Advantage The MAF Test targets breast cancer adjuvant therapy to predict bisphosphonate response, offering a precision medicine angle for oncologists and pathologists. Position the product as a tool to optimize treatment plans, reduce relapse risk, and differentiate from generic biomarker offerings in oncology diagnostics.

Validation Momentum Historical Phase 3 AZURE analyses and ongoing clinical results underscore credibility and can be leveraged in pitches to hospitals and payers. Emphasize published outcomes and regulatory-readiness to accelerate adoption and reimbursement discussions.

Regional Focus Recent South Korea launch agreement and established Iberian distribution indicate a multi-region go-to-market approach. Tailor market-entry strategies for each region, including regulatory considerations, KOL engagement, and localized clinical workflows to maximize adoption speed.

Funding & Growth With revenue in the lower mid-range and a modest funding base, there is room to pursue strategic investments in sales force expansion, key account management, and payer partnerships. Target multi-tier partnerships with diagnostic labs and hospital systems to scale reach efficiently.